Differential responsiveness to IL-2, IL-7, and IL-15 common receptor γ Chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients

Journal of Immunotherapy

Volumn 32, Issue 3, 2009, Pages 252-261

  Rosenthal, Rachel ^a   Groeper, Célia ^a   Bracci, Laura ^a   Adamina, Michel ^a   Feder Mengus, Chantal ^a   Zajac, Paul ^a   Iezzi, Giandomenica ^a   Bolli, Martin ^a   Weber, Walter P ^a   Frey, Daniel M ^a   Von Holzen, Urs ^b   Oertli, Daniel ^a   Heberer, Michael ^a   Spagnoli, Giulio C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Olten ^*  (Switzerland)

Author keywords

Common receptor g chain cytokines; Melanoma immunotherapy; Naive and memory CD8+ T lymphocytes

Indexed keywords

CD45RA ANTIGEN; HLA A ANTIGEN; MELAN A; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 7; PEPTIDE; VIRUS ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; COMPARATIVE STUDY; DRUG EFFECT; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM;

ANTIGENS, VIRAL; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; MELANOMA; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 67449095312     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181998e03     Document Type: Article

References (51)

1. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2:251-262.
2. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3:269-279.
3. Meidenbauer N, Marienhagen J, Laumer M, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol. 2003;170:2161-2169.
4. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
5. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99:3892-3904.
6. Lynch DH, Miller RE. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med. 1994;179:31-42.
7. + T cells. J Exp Med. 2002;195:1533-1539.
8. Schluns KS, Kieper WC, Jameson SC, et al. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol. 2000;1:426-432.
9. Berard M, Brandt K, Bulfone-Paus S, et al. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol. 2003;170:5018-5026.
10. + T cells. J Exp Med. 2002;195:1515-1522.
11. + memory T cells by opposing cytokines. Science. 2000;288:675-678.
12. + cells. J Exp Med. 2002;195:1523-1532.
13. Zhang X, Sun S, Hwang I, et al. Potent and selective stimulation of memory-phenotype CD8 + T cells in vivo by IL-15. Immunity. 1998;8:591-599.
14. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32.
15. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
16. Zajac P, Oertli D, Marti W, et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther. 2003; 14:1497-1510.
17. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
18. Rosenberg SA, Sportes C, Ahmadzadeh M, et al. IL-7 administration to humans leads to expansion of CD8 + and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006;29:313-319.
19. Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go? Nat Clin Pract Oncol. 2006;3:668-681.
20. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
21. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphode-pleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
22. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005;11:1230-1237.
23. Alves NL, Hooibrink B, Arosa FA, et al. IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro. Blood. 2003; 102:2541-2546.
24. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood. 2003;101:4260-4266.
25. Kanegane H, Tosato G. Activation of naive and memory T cells by interleukin-15. Blood. 1996;88:230-235.
26. Liu K, Catalfamo M, Li Y, et al. IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci USA. 2002;99:6192-6197.
27. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
28. Herndler-Brandstetter D, Schwaiger S, Veel E, et al. CD25-expressing CD8 + T cells are potent memory cells in old age. J Immunol. 2005;175:1566-1574.
29. Kern F, Surel IP, Brock C, et al. T-cell epitope mapping by flow cytometry. Nat Med. 1998;4:975-978.
30. Catalina MD, Sullivan JL, Bak KR, et al. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol. 2001;167: 4450-4457.
31. Blanchet JS, Valmori D, Dufau I, et al. A new generation of Melan-A/MART-1 peptides that fulfill both increased immu-nogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J Immunol. 2001;167:5852-5861.
32. Dunbar PR, Smith CL, Chao D, et al. A shift in the phenotype of Melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol. 2000;165: 6644-6652.
33. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999;190:705-715.
34. Zippelius A, Pittet MJ, Batard P, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med. 2002;195:485-494.
35. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self-antigen triggers human CD8T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA. 2008; 105:3849-3854.
36. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001;14:105-110.
37. Cassatella MA, McDonald PP. Interleukin-15 and its impact on neutrophil function. Curr Opin Hematol. 2000;7:174-177.
38. Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescues tolerant CD8 + T cells for use in adoptive immunotherapy of established tumors. Nat Med. 2006;12:335-341.
39. Dubois S, Mariner J, Waldmann TA, et al. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002;17:537-547.
40. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
41. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253-261.
42. Wan YY, Flavell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev. 2006;212: 114-130.
43. Cousens LP, Orange JS, Biron CA. Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. J Immunol. 1995;155:5690-5699.
44. Kramer S, Mamalaki C, Horak I, et al. Thymic selection and peptide-induced activation of T cell receptor-transgenic CD8 T cells in interleukin-2-deficient mice. Eur J Immunol. 1994;24: 2317-2322.
45. Kundig TM, Schorle H, Bachmann MF, et al. Immune responses in interleukin-2-deficient mice. Science. 1993;262:1059-1061.
46. Kroemer G, Martinez C. Interleukin-2, a pro-autoimmune lymphokine that interferes with post-deletional tolerance. Semin Immunol. 1992;4:167-179.
47. Heath WR, Allison J, Hoffmann MW, et al. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature. 1992;359:547-549.
48. Schattner A. Lymphokines in autoimmunity - a critical review. Clin Immunol Immunopathol. 1994;70:177-189.
49. Gotter J, Brors B, Hergenhahn M, et al. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med. 2004;199:155-166.
50. Schumacher R, Amacker M, Neuhaus D, et al. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine. 2005;23:5572-5582.
51. Antony PA, Paulos CM, Ahmadzadeh M, et al. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol. 2006;176:5255-5266.